The possibility of achieving multiple systemic expression of human interferon-␤ in mice upon repeated intravenous administration of cationic liposome-DNA complex (lipoplex) was investigated. Lipoplexes containing the pentammonio lipid pcTG90 were first optimized by selecting the most efficient ratio of pcTG90 to phosphatidylethanolamine (DOPE) and the N/P ratio of cationic lipid nitrogen to DNA phosphate. Highest levels and reproducibility of gene expression were obtained using pcTG90/DOPE (1:2) liposomes complexed with the IFNB1 gene containing plasmid pTG14169 at a N/P ratio of 10. Following lipoplex administration, an early but transient human interferon-␤ expression in serum was observed. Importantly, repeated systemic
Introduction
Cationic liposome-plasmid DNA complexes (lipoplexes) 1 can mediate transgene expression in vivo and represent an alternative approach to the use of viral vectors in gene therapy. [2] [3] [4] Because synthetic vectors lack potential disadvantages of viral systems including possible presence of replication-competent virions, insertional mutagenesis and more particularly specific immune response, they may represent more suitable gene delivery systems for repetitive use. Despite a growing number of cationic liposome-based systems tested in human clinical trial protocols since 1993, clinical applications of lipoplexes are, however, still limited by both their moderate level and transient duration of gene expression upon intravenous administration. Short duration of gene expression is a general drawback for all synthetic vectors that may be overcome by repeated dosing.
Interferon gene therapy may offer a beneficial strategy over direct systemic administration of recombinant proteins which anticancer therapeutic efficacy suffers from the very short half-life in the circulation, 5, 6 and the high dose-associated toxic side-effects of the protein. 7 Here we used IFNB1 as a reporter gene for the optimization of gene expression could be achieved upon re-administration with a minimal time interval of 14 days between two injections. For an interval period of 6 days, subsequent gene expression was inhibited by a first administration of lipoplexes containing either a luciferase reporter gene plasmid or an empty plasmid, but was not inhibited when free (noncomplexed) plasmid pTG14169 was first injected. Multiple injections of pcTG90-lipoplex performed once every other month resulted in three subsequent peaks of systemic IFNB1 gene expression in mice. In conclusion, our study demonstrates the feasibility of expanding the therapeutic window of a cytokine using repetitive intravenous administration of lipoplex. Gene Therapy (2000) 7, 1606-1611.
lipoplex-mediated expression of cytokines and other classes of biologically active circulating proteins.
We report here that optimization of the cationic lipid pcTG90-based lipoplex resulted in high levels of IFNB1 gene expression in mice. Although gene expression was transient, re-administration of optimized lipoplex could generate subsequent systemic expression peak levels of the transgene. Ineffectiveness of a second administration performed less than 2 weeks after the initial one was caused by initial lipoplex injection, but was not related to the initial systemic expression of human IFN-␤. Finally, injection of optimized pcTG90-lipoplex once every other month for 2 months resulted in three subsequent human IFN-␤ gene expression peaks showing that increased duration of gene expression can be accomplished via multiple intravenous administrations of cationic liposomebased gene vectors.
Results
Optimization of pcTG90-lipoplex for systemic expression of human IFN-␤ in mice Before evaluating the use of pcTG90-based systems upon repeated dosing, lipoplex optimization was performed by investigating the effect of pcTG90/DOPE molar ratio and N/P ratio of cationic lipid nitrogen to DNA phosphate on in vivo transfection efficiency. Results in Figure 1a show that systemic gene expression levels of human IFN-␤ increased with increasing amount of DOPE in the lipo- plexes at a ratio of N/P = 5. Lipoplexes made of pcTG90/DOPE (1:2) yielded two-and eight-fold higher gene expression levels than in the case of pcTG90/DOPE (1:1) and pcTG90-lipoplexes lacking DOPE, respectively. Further increase in the relative amount of DOPE did not result in higher lipoplex activity (not shown).
The N/P ratio had a much stronger effect on transfection efficiency than the lipid composition at a given N/P ratio, allowing significant optimization of complexes. pcTG90/DOPE (1:2)-pTG14169 lipoplexes became more efficient with N/P values in the order of 3 Ͻ 5 Ͻ 10 ( Figure 1b) . At a N/P = 10, lipoplexes resulted in secreted IFN-␤ levels of about 75 IU/ml (approximately 3.75 ng/ml) in mice serum. Increasing the N/P ratio to 15 did not further increase gene expression levels.
Colloidal and functional stability of optimized lipoplexes upon prolonged storage Optimized lipoplexes showed high colloidal and functional stability when stored for 6 weeks at 4°C. Over this Gene Therapy period, the mean particle diameter of pcTG90/DOPE (1:2)-pTG11469 lipoplexes at N/P = 10 (about 150 nm) remained unchanged, complexes retained their plasmid DNA content (gel electrophoresis, data not shown) and, most importantly, their in vivo gene transfer efficiency ( Figure 2 ).
Duration of transgene expression
The kinetics of gene expression was short-term and transient ( Figure 3 ). Relatively high transgene expression was obtained as early as 5 h after injection (about 50% of the peak level) and increased over time until reaching a maximum at 18 h. At later time points, the level of human IFN-␤ gradually decreased to about 8% of its maximum value after 48 h and became undetectable after 72 h.
Repeated gene expression depends on time interval between two injections
Repeated administration of pcTG90/DOPE (1:2)-pTG14169 lipoplexes at N/P = 10 was performed at dif- ferent time intervals between the first and the second injection ( Figure 4 ). Three groups of mice were injected on day 0 and the second injection was performed at either 6, 10 or 14 days after the initial injection in the first, second and third group, respectively. In all cases, level of gene expression was determined 24 h after injection. Results show no detectable production of human IFN-␤ when the second administration was performed either at 6 or 10 days after the initial injection. On the contrary, significant expression (about 1/3 of the initial peak level) could be obtained when a time interval of 14 days was respected.
Expression of the transgene is not the cause for inhibition of subsequent expression upon readministration We tested whether a first expression peak of a non-homologous transgene (in this case, the human interferon-␤ in the mouse) could be the cause for the inhibition of a second expression upon re-administration. Therefore, an initial injection was performed with either lipoplexes containing the plasmid coding for the IFNB1 gene, or a plasmid containing the luciferase reporter gene (pTG11236), or a non-coding plasmid (pTG11022). Another group of mice was first given the naked IFNB1-coding plasmid pTG14169. In all cases, the second administration with pcTG90/DOPE (1:2)-pTG14169 was performed 6 days after the first injection and systemic gene expression levels were determined 24 h later. Results presented in Figure 5 show that whatever the type of lipoplex injected initially, the second injection did not result in detectable gene expression in mice serum. On the contrary, there was no inhibition of transgene expression when naked DNA was first given to mice. In mice that received the free plasmid, no significant gene expression was detected in mice serum 24 h after intravenous injection. 
Evaluation of gene expression upon multiple intravenous administration of optimized lipoplex
To test whether a longer time interval between two injections would allow a second expression level identical to the initial one and if more than two injections could generate more than two expression peaks, mice were injected once every other month for 2 months with optimized pcTG90/DOPE (1:2)-pTG14169 lipoplexes. A total of three injections with an interval of 30 days between two injections resulted in three peaks of systemic gene expression at 24 h after each injection ( Figure 6 ). Results show a tendency for expression levels to decrease with increasing number of subsequent injections. However, no statistical differences could be shown in a pair-wise comparison between expression levels resulting from the second and the third administration.
Discussion
We optimized lipoplex formulation containing the pentammonio lipid pcTG90 before investigating its potential use for repeated administration. At a N/P = 5, transfection activity of pcTG90-lipoplexes was significantly enhanced by addition of the colipid DOPE. Recent studies have reported that inclusion of DOPE into either DOTAP or DOTMA liposomes significantly decreased their transfection activity in mice, 8 and that contrary to what is usually observed in cell culture systems, cholesterol but not DOPE, was more effective in sustaining high transfection activity in vivo. [9] [10] [11] Our observations now suggest that neither DOPE nor cholesterol is a priori the optimal colipid to use. Rather, miscibility between a given cationic lipid and colipid together with the type of micellar/lamellar phases formed by lipid mixtures in aqueous solution are likely to be involved in lipoplex efficiency in vivo via their size, shape, surface charge density, and stability under physiological conditions. 12 The influence of all these parameters may also explain why
Figure 6 Lipoplex-mediated multiple systemic gene expression upon repeated administration. Optimized lipoplexes (pcTG90/DOPE (1:2)-pTG14169, N/P = 10) were injected once every other month for 2 months in the same group of mice. 24 h after injection, the systemic level of human IFN-␤ was quantitated by ELISA. Each sample was injected at a dose of 60 g DNA per animal. Data are presented as means ± s.e.m. (n = 10). Statistically significant differences were found between J0 and J30 (P р 0.05), but not between J30 and J60 (P Ͼ 0.05).
optimal lipoplex activity was observed at a given pcTG90/DOPE molar ratio.
A remarkably pronounced enhancement of transfection efficiency was observed by increasing the N/P ratio of lipoplexes. Since increasing the N/P ratio increases the lipid/DNA ratio, an excess of cationic liposomes in the lipoplex preparation may account for enhanced transgene expression. Indeed, it has been shown that intravenous administration of a lipoplex preparation already containing an uncomplexed cationic liposome population, 13 or pre-injection of free cationic liposomes, 14 enhances lipoplex activity. Although such observations were reported in the case of chloramphenicol acetyltransferase or luciferase reporter gene expression in various organs, our results suggest that this phenomenon also applies for circulating proteins. Using our optimized lipoplex formulation, levels of human IFN-␤ found in mice serum (20-100 IU/ml or 1-5 ng/ml) were well in the range of therapeutic levels for IFN-␤, 6 and other circulating proteins such as transforming growth factor-␤1, 15 human factor VIII, 16 erythropoietin, 17 or endostatin. 18 Levels of circulating human IFN-␤ were detectable for about 3 days following lipoplex injection. This already represents a potential advantage of using a cytokine gene therapy approach over direct intravenous bolus injection of recombinant IFN-␤ for which pharmacokinetics correlated with a two-compartment model with a distribution and terminal half-life of about 5 min and 5 h, respectively. 6 However, a few days' systemic expression of a cytokine may still not be sufficient for successful antiviral/anticancer therapy. One way to circumvent the potential limitations due to a short time-course of gene expression after gene delivery by synthetic vectors Gene Therapy resides in repeated administration. In addition, multiple dosing may additionally allow the modulation of the number and frequency of administrations in a controlled manner for optimal and individual treatment regimens.
Importantly, our study demonstrates that repeated systemic gene expression of a therapeutic protein could be achieved upon re-administration of lipoplexes. Further investigation is, however, required to determine the reasons why a minimal time period of about 2 weeks between two injections is necessary to allow subsequent gene expression. It was recently shown that luciferase expression in lungs was not effective if a second dose of lipoplexes, 11 or lipid-protamine-DNA complexes, 19 was administered at short time intervals. This phenomenon is thought to be due to inhibition of gene expression by host secondary cytokines induced after the first intravenous administration of the complexes. 19 In the present case, we have shown that the 2-week interval could not correspond to an acquired immune response against expressed human IFN-␤ in mice since lipoplex containing a luciferase reporter gene also completely inhibited a second interferon-␤ gene expression upon re-administration. As suggested by Li et al, 19 inflammation and/or transfected cell death may account for the requirements of a recovery period.
On the other hand, we could show that multiple injections are possible if the minimal intervals between injections are respected. Using a 1-month interval between two injections, three intravenous administrations of optimized lipoplex resulted in significant circulating human IFN-␤ levels 24 h following each injection. These data demonstrate the possibility of multiple dosing for prolonged gene expression. We observed, however, that the level of expression decreased with increasing injection number. Several hypotheses can be considered to explain this observation. For example, transfection efficiency of lipoplex may decrease with increasing animal aging, or because 30 days is still a too short interval between subsequent administrations for complete transfected tissue recovery. The kinetics of gene expression following the first and the subsequent injections may also be different, resulting in distinct peak levels of gene expression at a fixed time-point (24 h) after injection. Finally, induction of specific mouse antibodies against human IFN-␤ may affect ELISA assay measurements. Further work is required to elucidate the origin of this phenomenon.
Together with colloidal and functional stability of synthetic vectors, safety issues are particularly crucial in the case of multiple dosing. Stabilization of cationic liposome complexes with plasmid DNA, 9 or oligonucleotides, 20 can be achieved by inclusion of polyethylene glycol-derivatized lipids. Stabilization of complexes by polyethylene glycol coating or by precondensation of plasmid DNA with polyamines can maintain their in vivo gene transfer activity for up to 2 months. 9 We found that optimized pcTG90-lipoplexes were stable in size, retained their DNA content and in vivo transfection activity for up to at least 6 weeks after they were prepared when stored at 4°C under argon without the use of additional stabilizing agents.
Injected mice did not show severe clinical signs throughout the whole study. However, the highest degree of abnormal behaviors such as reduced activity generally occurred 24 h following intravenous injection and 10-15% body weight loss was observed 2-3 days after lipoplex administration. These signs of toxicity were transient and mice generally recovered completely 5 to 6 days after injection.
In summary, optimized pcTG90-based lipoplex is a stable and efficient synthetic gene delivery system capable of generating multiple therapeutic systemic levels of a cytokine upon repeated dosing. These findings provide evidence that lipoplexes may become acceptable gene therapy products for the systemic gene delivery and expression of therapeutic proteins.
Materials and methods

Chemicals
Cationic lipid pcTG90 was synthesized as described previously, 21 and the colipid DOPE was purchased from Avanti Polar Lipids (Alabaster, AL, USA). All other chemicals and solvents used were of analytical grade. Aqueous solutions were sterilized by passage through 0.2 m pore filters before use.
Plasmids
Human interferon-␤ gene containing plasmid pTG14169 contains a CMV immediate-early promoter, a genomic IFNB1 coding region, a SV40 poly (A) signal and the SV40 16S/19S hybrid intron. pTG11236 and pTG11022 plasmids are identical to plasmid pTG14169 except that they contain the luciferase reporter gene instead of IFNB1 or no coding sequence, respectively. All plasmids were purified using the CsCl-ethidium bromide gradient centrifugation method, 22 tested for the presence of endotoxins (Ͻ20 endotoxin units per milligram), and quantitated by ultraviolet absorbance at 260 nm.
Preparation of cationic liposomes and lipoplexes
Lipids were mixed in chloroform at the desired molar ratios and the solvent was evaporated under reduced pressure using a Labconco Rapidvap vortex evaporator (Uniequip, Martinsried, Germany) at 45°C for at least 4 h with a rotation speed of 45 r.p.m. The resulting dried lipid film was hydrated in a 5% (w/v) glucose aqueous solution (5-15 mg/ml cationic lipid) and sonicated until the lipid suspension becomes optically clear using a Bransonic 221 ultrasonic water bath (Branson Ultrasonics, Danbury, CT, USA). Resulting liposomes were then extruded once through 0.2 m pore membrane (Nuclepore; Costar, Cambridge, MA, USA) under sterile atmosphere using a nitrogen pressure extruder (Lipex Biomembranes, Vancouver, Canada).
Corresponding lipoplexes were formed by mixing plasmid DNA with cationic liposomes. Plasmid DNA was first diluted in 5% glucose to the desired concentration and lipoplex formation was done by rapid addition of extruded liposome suspension to the plasmid solution (volume of liposomal suspension/volume of plasmid DNA solution approximately 1/3). All lipoplexes were prepared at a final plasmid concentration of 240 g/ml and kept for at least an overnight time period at 4°C before use.
Lipid assays
High-performance liquid chromatography (HPLC) was used for quantitation of liposome lipid content before lipoplex formation. A protocol has been developed allowing direct separation and quantitation of all lipids from preformed liposomes without lipid extraction. Briefly, a reversed-phase (25 × 0.46 cm) C 18 LC ABZ plus + column (Supelcosil; Supelco, Bellefonte, PA, USA) was used on a HP1090 HPLC system (Hewlett-Packard, Camas, WA, USA). One hundred microliters of each sample previously diluted in a final volume containing 50% isopropanol were injected and lipids were eluted using a gradient starting from a mixture of 50% solution A (water/trifluoroacetatic acid-triethylamine 17 mm, pH 4), and 50% solution B (isopropanol 100%) to 100% solution B at a flow rate of 0.5 ml/min. Ultraviolet detection was performed at 205 nm. Quantitation of DOPE was additionally performed by phosphorus assay. 23 Particle size determination Particle diameter of cationic liposomes and resulting lipoplexes was determined by dynamic laser light scattering using a Coulter N4 Plus submicron particle sizer (Coultronics France, Margency, France). Measurements were performed within a 3-10 000 nm size window with a fixed 90°scattered light angle. Hydrodynamic mean diameter of optimized lipoplexes was typically 150 ± 55 nm using unimodal distribution mode.
In vivo gene delivery and expression analyses Lipoplexes were administered via tail vein injection to 9-week-old female B6SJLF1 mice (Iffa-Credo, l'Arbresle, France). In all cases, each animal received 60 g of plasmid DNA in 250 l. At given time-points after administration, blood samples were collected either via retroorbital puncture from live animals or by heart puncture from dead animals. Blood samples were left at 4°C for at least 4 h and serum was separated by centrifugation. Isolated sera were frozen and kept at −20°C until human IFN-␤ protein determination by ELISA with minimum significant sensitivity of 2.5 IU/ml (human IFN-␤ kit, Furebio, Tokyo, Japan). Conversion from units to nanograms was calculated from a specific activity of 2 × 10 7 units/mg according to the biological activity of human IFN-␤ from Leinco Technologies. Luciferase expression analysis was performed as described previously. 24 
Statistical analysis
Human IFN-␤ ELISA data were analyzed using the nonparametric Mann-Whitney U test in a pair-wise comparison. Statistical significance was defined as a P р 0.05.
